Jeffrey Stein - 27 Mar 2023 Form 4 Insider Report for Cidara Therapeutics, Inc. (CDTX)

Role: President & CEO, Director
Signature: /s/ Shane Ward, Attorney-in-Fact
Issuer symbol: CDTX
Transactions as of: 27 Mar 2023
Net transactions value: +$51,855
Form type: 4
Filing time: 27 Mar 2023, 19:03:20 UTC
Previous filing: 23 Feb 2023
Next filing: 09 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CDTX	Common Stock	Purchase	$51,855	+50,000	+22%	$1.04	281,602	27 Mar 2023	By trust	F1
holding	CDTX	Common Stock						922,635	27 Mar 2023	Direct
holding	CDTX	Common Stock						42,009	27 Mar 2023	By son

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.015 to $1.0599. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.015 to $1.0599. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.